KA
RPRX icon

Kearns & Associates’s Royalty Pharma RPRX Stock Holding History

Kearns & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.4M Hold
58,240
– – 1.56% 8
2026
Q2 		$3.27M Hold
58,240
– – 1.52% 8
2026
Q1 		$2.79M Sell
58,240
-12,500
-18% -$547K 1.5% 8
2025
Q4 		$2.73M Hold
70,740
– – 1.41% 8
2025
Q3 		$2.5M Hold
70,740
– – 1.32% 8
2025
Q2 		$2.55M Hold
70,740
– – 1.46% 8
2025
Q1 		$2.2M Buy
70,740
+53,055
+300% +$1.68M 1.43% 8
2024
Q4 		$451K Buy
+17,685
New +$469K 0.29% 29

Other funds holding RPRX

Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $53.6B AUM 32.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Achmea Investment Management
Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Fideuram Asset Management (Ireland)
Fideuram Asset Management (Ireland) Dublin 1 $4.57B AUM 30.36% 1-Year Est. Return
Todd Asset Management
Todd Asset Management Louisville, Kentucky $5.51B AUM 33.77% 1-Year Est. Return

Kearns & Associates's RPRX Position: Q3 2026 in Review

Kearns & Associates held its Royalty Pharma (RPRX) position steady in Q3 2026 at 58,240 shares worth $3.4M. The position accounts for 1.56% of the portfolio, ranked #8.

Kearns & Associates first reported a position in RPRX in Q4 2024 and has held it in 8 quarters since. 208 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • Kearns & Associates held 58,240 shares of Royalty Pharma worth $3.4M as of Q3 2026.
  • Kearns & Associates left its Royalty Pharma share count unchanged in Q3 2026.
  • Royalty Pharma made up 1.56% of Kearns & Associates's portfolio in Q3 2026, its #8 holding.
  • Kearns & Associates first reported a position in Royalty Pharma in Q4 2024 and has held it in 8 quarters since.
  • 208 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Kearns & Associates's 13F filing for Q3 2026, filed 9 Oct 2026.